Achillion shares spike on promising hep C data

Shares of Achillion Pharmaceuticals jumped 22 percent after the developer announced that preliminary data from an early-stage trial demonstrated that its hepatitis C drug was effective on a once-daily dose using a lower dosage. ACH-1625 spurred meaningful drops in virus levels after five days of treatment. "We remain very encouraged by these compelling results and look forward to advancing the drug into Phase 2 studies in the coming months," Chief Executive Michael Kishbauch said in a statement. Achillion release | Report

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.